|Awarded On||May 17, 2023|
|Title||IND-Enabling Studies of ONP-001: A Nano-Codelivery Formulation with Two Drugs of Distinct Mechanisms of Action for Treating Pancreatic Ductal Adenocarcinoma|
|Program||Product Development Research|
|Award Mechanism||Seed Awards for Product Development Research|
|Institution/Organization||OmniNano Pharmaceuticals LLC|
|Principal Investigator/Program Director||Guorong Ma|
*Pending contract negotiation
OmniNano Pharmaceuticals is a pharmaceutical technology startup located in Missouri City, TX. Omninano is developing nano-codelivery formulations with two drugs of distinct mechanisms of action for treating solid tumors. The foundational work has been done at the University of Texas MD Anderson Cancer Center and the University of Houston. Our lead product, ONP-001 is designed to treat pancreatic cancer. In 2022, 62,210 new pancreatic cases will be diagnosed in the US, with 49,830 deaths and a 5-year survival rate of only 11.5%. Extant drug therapies have very limited efficacy, with more than half of all pancreatic cancer patients dying within 12 months of diagnosis. Furthermore, current trea...